The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
17 Jun 2022
17 Jun 2022
Historique:
received:
20
10
2021
accepted:
17
05
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Carriers of germline BRCA2 pathogenic sequence variants have elevated aggressive prostate cancer risk and are candidates for precision oncology treatments. We examined whether BRCA2-deficient (BRCA2
Identifiants
pubmed: 35715489
doi: 10.1038/s41698-022-00284-6
pii: 10.1038/s41698-022-00284-6
pmc: PMC9205939
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39Subventions
Organisme : NCI NIH HHS
ID : R00 CA245900
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R00-CA245900
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R01-CA207365
Informations de copyright
© 2022. The Author(s).
Références
Database (Oxford). 2010 Aug 05;2010:baq020
pubmed: 20689021
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Nucleic Acids Res. 2018 Oct 12;46(18):9891
pubmed: 30165642
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
J Clin Oncol. 2019 Feb 20;37(6):490-503
pubmed: 30625039
Prostate. 2019 Jun;79(8):880-895
pubmed: 30900310
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Cancer Res. 1999 Apr 1;59(7 Suppl):1752s-1756s
pubmed: 10197592
Eur J Cancer. 2021 Apr;147:74-83
pubmed: 33626496
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Clin Cancer Res. 2020 Apr 15;26(8):2047-2064
pubmed: 31796516
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
PLoS Genet. 2021 May 4;17(5):e1009557
pubmed: 33945534
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Clin Cancer Res. 2020 Jun 1;26(11):2673-2680
pubmed: 32071115
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3030-5
pubmed: 19861517
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
Genome Biol. 2020 Feb 20;21(1):43
pubmed: 32079540
EMBO Rep. 2016 Nov;17(11):1609-1623
pubmed: 27596623
Ann Oncol. 2015 Nov;26(11):2293-300
pubmed: 26347108
Cancer Invest. 2006 Nov;24(7):682-8
pubmed: 17118778
Genes Chromosomes Cancer. 2018 Oct;57(10):504-512
pubmed: 29923647
Mod Pathol. 2018 Jan;31(S1):S1-11
pubmed: 29297493
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Oncotarget. 2019 Jun 18;10(40):4018-4025
pubmed: 31258846
Clin Cancer Res. 1997 Oct;3(10):1867-72
pubmed: 9815575
Cancer Discov. 2017 Sep;7(9):973-983
pubmed: 28515055
PLoS Genet. 2020 Feb 14;16(2):e1008641
pubmed: 32059012
Hum Pathol. 1996 Jan;27(1):28-34
pubmed: 8543307
Elife. 2015 Sep 16;4:
pubmed: 26374986
Cancer Treat Rev. 2015 Nov;41(9):761-6
pubmed: 26210103
Br J Cancer. 2008 Jan 29;98(2):502-7
pubmed: 18182994
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Eur Urol. 2019 Dec;76(6):831-842
pubmed: 31537406
Clin Cancer Res. 2007 Oct 15;13(20):6122-9
pubmed: 17947477
Nat Commun. 2017 Jan 09;8:13671
pubmed: 28067867
J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6
pubmed: 10433620
Am J Hum Genet. 2016 May 5;98(5):818-829
pubmed: 27087322
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Mol Endocrinol. 2007 Aug;21(8):1835-46
pubmed: 17505060
Oncogene. 2018 Mar;37(10):1354-1368
pubmed: 29269867
Cancer Prev Res (Phila). 2011 Jul;4(7):1002-10
pubmed: 21733824
Ann Oncol. 2013 May;24(5):1416-8
pubmed: 23524863
Br J Cancer. 2011 Oct 11;105(8):1230-4
pubmed: 21952622